{"id":578202,"date":"2026-04-09T00:00:00","date_gmt":"2026-04-09T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0046-2026-biopharma-atopic-dermatitis-atopic-eczema-current-treatment-treatment-algorithms-claims-data-analysis\/"},"modified":"2026-04-14T10:10:18","modified_gmt":"2026-04-14T10:10:18","slug":"algoim0046-2026-biopharma-atopic-dermatitis-atopic-eczema-current-treatment-treatment-algorithms-claims-data-analysis","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0046-2026-biopharma-atopic-dermatitis-atopic-eczema-current-treatment-treatment-algorithms-claims-data-analysis\/","title":{"rendered":"Atopic Dermatitis \/ Atopic Eczema &#8211; Current Treatment &#8211; Treatment Algorithms: Claims Data Analysis &#8211; Atopic Dermatitis (Pediatric) (US)"},"content":{"rendered":"<p>Atopic dermatitis (<abbr data-abbreviation-entity=\"7654\" title=\"atopic dermatitis\">AD<\/abbr>) is a chronic, itchy, inflammatory skin disease often starting in childhood. It is usually treated with topical immunotherapy. Refractory cases may need systemic immunomodulators with long-term risks. The launch of biologics (Dupixent, Adbry, Ebglyss, Nemluvio), <abbr data-abbreviation-entity=\"7988\" title=\"Janus kinase\">JAK<\/abbr> inhibitors (Rinvoq, Cibinqo, Opzelura), and non-steroidal agents (Vtama, Zoryve, Eucrisa) has greatly expanded treatment options for pediatric <abbr data-abbreviation-entity=\"7654\" title=\"atopic dermatitis\">AD<\/abbr> patients across the severity spectrum. This claims data analysis explores the usage pattern of newer therapies relative to historical mainstays, offering insight into evolving drug trends in pediatric <abbr data-abbreviation-entity=\"7654\" title=\"atopic dermatitis\">AD<\/abbr>.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What patient shares do key therapies and brands garner by line of therapy in newly diagnosed pediatric <abbr data-abbreviation-entity=\"7654\" title=\"atopic dermatitis\">AD<\/abbr> patients? What are the quarterly trends in prescribing recently treated and newly diagnosed pediatric <abbr data-abbreviation-entity=\"7654\" title=\"atopic dermatitis\">AD<\/abbr> patients?<\/li>\n<li>How have newer-to-market targeted therapies been integrated into the treatment algorithm, and what is their source of business?<\/li>\n<li>What percentage of pediatric <abbr data-abbreviation-entity=\"7654\" title=\"atopic dermatitis\">AD<\/abbr> patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?<\/li>\n<li>What percentage of pediatric <abbr data-abbreviation-entity=\"7654\" title=\"atopic dermatitis\">AD<\/abbr> patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?<\/li>\n<\/ul>\n<p><b>Geography: <\/b>United States<\/p>\n<p><strong>Real-world data:<\/strong> U.S. pharmacy and medical claims data<\/p>\n<p><strong>Key drugs covered:<\/strong> Adbry, Cibinqo, Dupixent, Ebglyss, Nemluvio, Opzelura, Rinvoq, Vtama, oral immunosuppressants, corticosteroids (topical and oral), topical calcineurin inhibitors<\/p>\n<p><strong>Key feature:<\/strong> Dashboard featuring interactive visuals, easy navigation, and expanded analyses<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p>Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Understand patient flow between lines of therapy.<\/li>\n<li>Evaluate your brand share against competitors.<\/li>\n<li>Accurately assess your source of business.<\/li>\n<li>Quantify opportunities at different stages of the treatment algorithm.<\/li>\n<\/ul>\n<p><strong>Product enhancement<\/strong><\/p>\n<p>Treatment Algorithms: Claims Data Analysis leverages Clarivate\u2019s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.<\/p>\n","protected":false},"template":"","class_list":["post-578202","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-current-treatment","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/578202","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/578202\/revisions"}],"predecessor-version":[{"id":578274,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/578202\/revisions\/578274"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=578202"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}